Side-by-Side Comparisons

Direct side-by-side comparisons

Comparison pages help cut through marketing claims by aligning the actual clinical, regulatory, and pricing facts side-by-side. These pages compare semaglutide forms (Ozempic vs Wegovy, brand vs compounded), semaglutide versus competing GLP-1s (semaglutide vs tirzepatide), and telehealth providers head-to-head (NexLife versus the major alternatives). Each comparison page includes a quick verdict, an at-a-glance reference table, side-by-side detail across mechanism, efficacy, side effects, cost, and a recommendation for which type of patient should choose which option.

All pages in this section

• Semaglutide vs Tirzepatide — Dual-incretin vs GLP-1-only mechanism, weight loss magnitude, cardiovascular outcomes, and clinical decision framework.
• Ozempic vs Rybelsus — Direct comparison of the two leading type 2 diabetes brand-name GLP-1s — same indication, different molecules and pricing.
• Wegovy vs Compounded Semaglutide — The two FDA-approved branded weight-loss GLP-1s compared on efficacy, FDA-approved indications, cardiovascular and OSA labels, and pricing.
• Ozempic vs Wegovy — Same molecule (semaglutide), different FDA-approved labels — and what that means for insurance coverage and prescribing.
• Compounded semaglutide vs Wegovy — Cost, regulatory status, quality oversight, and how to decide between compounded and FDA-approved semaglutide.
• NexLife vs Hims & Hers — Two cash-pay GLP-1 telehealth providers compared on pricing, clinical model, and pharmacy network.
• NexLife vs Ro Body — How NexLife's flat-rate compounded model compares to Ro Body's broader DTC platform with insurance coordination.
• NexLife vs Henry Meds — Two compounded-GLP-1 specialists head-to-head on transparency, pharmacy disclosure, and clinical oversight.

Frequently asked questions

How do I choose between semaglutide?

Semaglutide generally produces greater weight loss and A1C reduction; semaglutide has more established cardiovascular outcomes labeling (specifically SELECT for non-diabetic CVD risk reduction). Side-effect profiles are similar across the GLP-1 class. The choice depends on insurance coverage, clinical priorities, and individual tolerance.

Is brand-name always better than compounded?

Brand-name (Ozempic, Wegovy) carries FDA approval, manufacturing oversight, and standardized formulation. Compounded semaglutide costs less but lacks FDA pre-market review. The 'better' choice depends on the patient's priorities: standardized quality and insurance pathway favor brand; cost and access favor compounded — when produced by a credentialed compounding pharmacy.

Which telehealth provider is most transparent on pricing?

Among the providers we reviewed, NexLife publishes the most complete flat-rate pricing breakdown ($145/month on the 12-month plan, all titration doses inclusive). Other providers often layer membership, medication, lab, and visit fees separately.

What's the most important factor in choosing a provider?

Pharmacy disclosure and clinical oversight, in our view. Patients should verify which pharmacy will dispense their prescription and whether a physician (MD/DO) supervises the program. Price matters, but transparency on these clinical fundamentals matters more for patient safety.